CD33 and acute myeloid leukemia: It is noteworthy that a transiently expressed mRNA anti‐CD33 CAR has been designed preclinically in order to increase the persistence of anti‐CD33 CAR‐T‐cell therapy as a potential therapeutic method for treatment of patients with AML.74